Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care Step Therapy Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentFidelis CarePolicy N/A

    2026 Step Therapy Criteria — Antidepressants, Antipsychotics (oral), Dextromethorphan/Bupropion, Trazodone

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Step therapy requirements for selected antidepressant, oral antipsychotic, dextromethorphan/bupropion, and trazodone products that govern prior trial requirements and exceptions for Fidelis Care members.

    Policy Summary
    PayerFidelis Care
    Policy2026 Step Therapy Criteria — Antidepressants, Antipsychotics (oral), Dextromethorphan/Bupropion, Trazodone
    Policy CodePolicy N/A
    Change TypeAdministrative update — no material clinical changes
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionProvide documentation of required prior Step 1 trials (at least a 1-day supply within the prior 180 days) when requesting prior authorization for Step 2 agents.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4therapeutic categories
    2step tiers
    180look-back (days)
    1-dayminimum trial supply

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3tablet strengths named

    Coverage Criteria — Step Therapy Requirements

    Antidepressants — Initial Step Therapy

    Coverage will be provided when ALL of the following are met:

    Antidepressant Step 1 trial: One Step 1 drug has been tried (at least a 1-day supply in the prior 180 days). Step 1 drugs include Bupropion SR/XL, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, or Venlafaxine IR/ER.1 drug tried

    Counts brand-name equivalent of a generic Step 1 product as meeting requirement

    Exceptions: Approve Exxua without prior trial if the patient has suicidal ideation, or approve if the patient is currently taking Exxua or has taken Exxua in the past.

    Oral Antipsychotics — Initial Step Therapy

    Coverage will be provided when ALL of the following are met:

    Antipsychotic Step 1 trials: Two Step 1 oral antipsychotic drugs have been tried (each at least a 1-day supply in the prior 180 days). Step 1 drugs include oral formulations of Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Lumateperone, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Xanomeline/Trospium, or Ziprasidone.2 drugs tried

    A trial of the brand name equivalent of a generic step 1 product will also count.

    Exceptions: Approve Fanapt if the patient is currently taking Fanapt or has taken Fanapt in the past.

    Dextromethorphan/Bupropion (Auvelity) — Initial Step Therapy

    Coverage will be provided when ALL of the following are met:

    SSRI/SNRI + Bupropion trial: Patient has tried 1) a generic SSRI or SNRI AND 2) bupropion (at least a 1-day supply in the prior 180 days).both classes tried
    Exceptions: Approve Auvelity if the patient has suicidal ideation without a trial of prerequisite drugs, or if the patient is currently taking or has taken Auvelity in the past.

    Trazodone — Initial Step Therapy

    Coverage will be provided when ALL of the following are met:

    Trazodone Step structure: Step 1 includes trazodone 100 mg and 150 mg tablets; Step 2 includes Raldesy 10 mg/mL oral solution.

    No additional criteria text provided in this part.

    No explicit clinical exclusions are listed in this section of the policy. The document defines the step requirements and exceptions (including suicidal ideation and prior/current use of Step 2 agents) but does not enumerate any standalone clinical exclusion criteria for the therapies covered here.

    There are no explicit exclusions stated for trazodone or Raldesy in this portion of the policy. The policy sets step-trial requirements and exceptions (e.g., inability to swallow tablets, current or prior use of Raldesy) rather than listing specific clinical exclusions.

    The policy does not list explicit denials for Step 2 products, but coverage is contingent on meeting the stated step requirements. In practice, a Step 2 product is not approved until the required Step 1 trials are documented (e.g., one Step 1 antidepressant trial for antidepressant Step 2 agents; two Step 1 oral antipsychotic trials for certain antipsychotic Step 2 agents; both a generic SSRI/SNRI and bupropion for Auvelity). Absent documentation of those required prior trials or an applicable exception, the Step 2 product will not meet coverage criteria.

    The policy does not explicitly state a separate denial list, but it establishes that Raldesy (the Step 2 trazodone oral solution) requires evidence of a prior tablet trial of generic trazodone (at least a 1-day supply within the prior 180 days) or a recognized exception (difficulty swallowing tablets, or current/prior use of Raldesy). If the prior tablet trial requirement is not met and no exception applies, coverage for the Step 2 oral solution is not supported.

    Coding and Look-back Definitions

    Covered oral tablet formulationsNDC | mixedCovered
    trazodone 50 mg tabletlisted tablet strength
    trazodone 100 mg tabletlisted tablet strength
    trazodone 150 mg tabletlisted tablet strength
    Covered oral tablet formulations (threshold)mixed
    >= 1-day supply in prior 180 daysPrior trial look-back requirement for tablet trial
    Covered oral solution (step 2)NDC | mixedCovered
    Raldesy 10 mg/mL oral solutionoral solution formulation (step 2)
    Covered oral solution (exceptions)mixed
    Patient cannot swallow tablets OR currently/previously taking RaldesyExceptions allowing approval without prior tablet trial
    Prior trial look-back (general)
    Look-back period>= 1-day supply in the prior 180 days
    Trial definitionA prior trial is counted when at least a 1-day supply of the Step 1 drug was dispensed within the prior 180 days.
    Acceptable productsStep 1 antidepressants include bupropion SR/XL, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine IR/ER.
    Prior trial look-back (tablet-specific)
    Look-back period (tablet-specific)>= 1-day supply within the prior 180 days
    Tablet form requiredCounts only a tablet dosage form of generic trazodone when meeting the prior tablet trial requirement.

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Antidepressants prior authorization — document one Step 1 trial

    Prior authorization requires documentation that the patient has tried one Step 1 antidepressant (at least a 1‑day supply within the prior 180 days) before approving the specified Step 2 antidepressant agent. Exceptions include documented suicidal ideation or current/prior use of the Step 2 product.

    • Step trial definition: ≥1-day supply in prior 180 days counts as a trial.
    • Step 1 drug list includes Bupropion SR/XL, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, or Venlafaxine.
    Prior Authorization

    Oral antipsychotics prior authorization — document two Step 1 trials

    Prior authorization for Step 2 oral antipsychotics requires documentation that two Step 1 oral antipsychotic drugs have been tried (each at least a 1‑day supply within the prior 180 days) before coverage of the Step 2 agent, unless the member is currently taking or has taken the Step 2 agent in the past.

    • A trial of the brand‑name equivalent of a generic Step 1 product will count toward the requirement.

    Background

    Step therapy is used in this policy to manage utilization and to encourage use of lower-cost or preferred therapies before advancing to Step 2 agents. The document specifies Step 1 product lists and defines a qualifying trial as at least a 1-day supply within the prior 180 days; certain Step 2 agents may be approved without prior trials when exceptions apply (for example, suicidal ideation or documented current/prior use of the Step 2 product). These step requirements and exceptions govern prior authorization decisions and determine when Step 2 products will be covered.

    Definitions and Exceptions

    Step trial definition
    Trial thresholdA trial is defined as at least a 1-day supply of the requisite Step 1 drug within the prior 180 days.
    Counting brand equivalentsA trial of the brand‑name equivalent of a generic Step 1 product will count toward the requirement.
    Applies to multiple classesUsed for antidepressant Step 1 requirements (list of specified generic SSRIs/SNRIs and bupropion SR/XL).
    Suicidal ideation exception
    Suicidal ideation exceptionCertain Step 2 agents may be approved without prior Step 1 trials if the patient has suicidal ideation (e.g., Exxua, Auvelity).
    Current or prior use exceptionApproval may also be granted if the patient is currently taking or has previously taken the Step 2 agent.

    Initial Therapy Criteria by Drug Class

    Antidepressants initial therapy

    Antidepressant initial therapy steps

    Step 1 trial required: One Step 1 antidepressant tried (≥1-day supply in prior 180 days).1 drug

    See Step 1 product list.

    Oral antipsychotics initial therapy

    Oral antipsychotics initial therapy

    Step 1 trials required: Two Step 1 oral antipsychotics tried (each ≥1-day supply in prior 180 days).2 drugs

    See Step 1 product list.

    Continuation Therapy and Exceptions

    Continuation therapy exceptions

    Continuation/allowance for current or prior use of Step 2 agent

    Current or prior use: Approve Step 2 agent if the patient is currently taking or has taken the agent in the past (documented).

    Applies to Exxua, Fanapt, Auvelity as specified.

    Step Therapy Tables

    StepRequirement / DescriptionCoverage Status
    Step 1: Specified Step 1 trials within the prior 180 days (at least a 1-day supply). For antidepressants this is one Step 1 drug (Bupropion SR/XL, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, or Venlafaxine IR/ER). For oral antipsychotics this is two Step 1 oral antipsychotic drugs (e.g., aripiprazole, asenapine, brexpiprazole, cariprazine, lumateperone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, xanomeline/trospium, or ziprasidone). For Auvelity require a generic SSRI or SNRI AND bupropion (each ≥1-day supply in prior 180 days).
    Step 2: Coverage of Step 2 agents is permitted after required Step 1 trials are documented. Exceptions allow approval of certain Step 2 agents (e.g., Exxua, Auvelity, Fanapt products) without prior trials if the patient has suicidal ideation or is currently taking / previously took the Step 2 agent.
    StepRequired TrialCoverage Status
    Trial of trazodone tablet dosage form (50 mg, 100 mg, or 150 mg) — patient must have used a tablet dosage form of generic trazodone for at least a 1-day supply within the prior 180 days.
    ProductApproval ConditionsCoverage Status
    May be approved after documentation of a prior tablet trial of generic trazodone (≥1-day supply in prior 180 days), or if the patient cannot swallow tablets, or if the patient is currently taking or has previously taken Raldesy.
    Policy Summary
    PayerFidelis Care
    Policy2026 Step Therapy Criteria — Antidepressants, Antipsychotics (oral), Dextromethorphan/Bupropion, Trazodone
    Policy CodePolicy N/A
    Change TypeAdministrative update — no material clinical changes
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionProvide documentation of required prior Step 1 trials (at least a 1-day supply within the prior 180 days) when requesting prior authorization for Step 2 agents.
    SourceLink
    On This Page
    Coverage Criteria — Step Therapy RequirementsCoding and Look-back DefinitionsProvider Actions, Prior Authorization & DocumentationBackgroundDefinitions and ExceptionsInitial Therapy Criteria by Drug ClassContinuation Therapy and ExceptionsStep Therapy Tables
    Example producttrazodone 50 mg tablet listed as a Step 1 tablet formulation.
  1. Step 1 product list includes oral formulations such as aripiprazole, lurasidone, quetiapine, olanzapine, risperidone, paliperidone, ziprasidone, etc.
  2. Prior Authorization

    Dextromethorphan/bupropion prior authorization — document SSRI/SNRI + bupropion trial

    Prior authorization for Auvelity (dextromethorphan/bupropion) requires documentation that the patient has tried a generic SSRI or SNRI AND bupropion (each at least a 1‑day supply within the prior 180 days), unless the patient has suicidal ideation or is currently/previously taking Auvelity.

    • Both classes must be documented (one generic SSRI or SNRI AND bupropion).
    • Approve without prior trial for suicidal ideation or current/prior Auvelity use.
    Prior Authorization

    Step therapy prior authorization — prior tablet trial for Raldesy

    Prior authorization for Raldesy requires documentation that the patient has used a generic trazodone tablet (at least a 1‑day supply within the prior 180 days) before approving Raldesy oral solution, unless the patient cannot swallow tablets or is currently/previously taking Raldesy.

    • Acceptable tablet strengths include generic trazodone 50 mg, 100 mg, or 150 mg.
    • If patient has difficulty swallowing tablets or is currently/previously on Raldesy, the prior tablet trial is not required.
    Step Therapy

    Antidepressants step logic — one Step 1 drug required

    For antidepressant step therapy, one Step 1 drug (from the listed SSRIs/SNRIs or bupropion SR/XL) must be tried (≥1‑day supply within the prior 180 days) before a Step 2 antidepressant will be approved; approval without trial is allowed for suicidal ideation or if the patient is currently/previously taking the Step 2 product.

    • Step 1 drug examples: Bupropion SR/XL, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Venlafaxine IR/ER.
    • A single Step 1 drug trial (≥1‑day supply in prior 180 days) satisfies the prerequisite.
    Step Therapy

    Oral antipsychotics step logic — two Step 1 trials required

    For oral antipsychotics, coverage of Step 2 agents requires documentation that two Step 1 oral antipsychotic drugs have each been tried (each at least a 1‑day supply within the prior 180 days); approve Step 2 if the patient is currently or previously taking that Step 2 agent.

    • Step 1 oral antipsychotics listed include aripiprazole, asenapine, brexpiprazole, cariprazine, lumateperone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, xanomeline/trospium, ziprasidone.
    • Trials of brand‑name equivalents of generics count toward the two‑drug requirement.
    Step Therapy

    Dextromethorphan/bupropion step logic — SSRI/SNRI + bupropion required

    Auvelity requires a documented trial of a generic SSRI or SNRI AND bupropion (each at least a 1‑day supply within the prior 180 days) before coverage will be approved; exceptions include suicidal ideation or current/prior Auvelity use.

    • Documentation must show both classes were tried within the look‑back period.
    • Suicidal ideation is an allowed exception to the prerequisite trials.
    Step Therapy

    Trazodone step logic — tablet Step 1 then Raldesy Step 2

    Step 1 for trazodone includes generic trazodone tablets (50 mg, 100 mg, or 150 mg); Step 2 is Raldesy 10 mg/mL oral solution. Approval of the Step 2 product requires meeting the Step 1 tablet trial requirement or qualifying for an exception.

    • Step 1 tablet strengths explicitly listed: 50 mg (in details), 100 mg, 150 mg.
    • Step 2 product: Raldesy 10 mg/mL oral solution.
    Step Therapy

    Step sequence — trazodone tablet trial then Raldesy or exception

    Step 1 requires a trial of a generic trazodone tablet (50 mg, 100 mg, or 150 mg) with at least a 1‑day supply within the prior 180 days; Step 2 is Raldesy 10 mg/mL oral solution and may be approved if step criteria are met or an exception (e.g., inability to swallow tablets or current/prior Raldesy use) applies.

    • Acceptable evidence of Step 1: dispensing or administration of at least a 1‑day supply of a generic trazodone tablet within prior 180 days.
    • Exceptions that permit Step 2 without tablet trial: difficulty swallowing tablets, inability to swallow tablets, or documented current/prior Raldesy use.
    Documentation Required

    Evidence of prior trials or exceptions — provide documentation

    Documentation must show evidence of prior Step 1 trials (at least a 1‑day supply within the prior 180 days) for the applicable therapy, or documentation of an approved exception such as suicidal ideation or current/prior use of the Step 2 agent.

    • Records should indicate dispensing or administration dates and quantities that demonstrate the ≥1‑day supply within the 180‑day look‑back.
    • Accepted exceptions: suicidal ideation or documented current/prior use of the Step 2 agent per each policy section.
    Documentation Required

    Required documentation — prior tablet trial or swallowing exception for Raldesy

    For Raldesy prior authorization, include documentation that the patient tried a generic trazodone tablet (≥1‑day supply within the prior 180 days), or document inability/difficulty swallowing tablets, or provide evidence the patient is currently or previously taking Raldesy.

    • If using the swallowing‑difficulty exception, include clinical notes documenting the inability to swallow tablets.
    • If relying on current/prior Raldesy use, include prior medication records showing Raldesy dispensing or administration.
    Denial Risk

    Antidepressants Step 1 prerequisite — risk of denial if not tried

    Coverage will be denied for Step 2 antidepressant agents when the prerequisite Step 1 drug has not been tried as required (a trial is defined as at least a 1‑day supply within the prior 180 days).

    • Verify a Step 1 trial (≥1‑day supply in prior 180 days) before submitting prior authorization to avoid denial.
    • Exceptions such as suicidal ideation or current/prior Step 2 use must be documented to support approval without Step 1 trial.
    Denial Risk

    Oral antipsychotics Step 1 prerequisite — denial risk without two trials

    Coverage may be denied for certain Step 2 oral antipsychotics unless two Step 1 oral antipsychotics have been tried and documented (each at least a 1‑day supply within the prior 180 days).

    • Document two distinct Step 1 oral antipsychotic trials within the 180‑day look‑back to meet the requirement.
    • Current or prior use of the Step 2 agent (e.g., Fanapt) is an alternative justification for approval and should be documented.
    Denial Risk

    Dextromethorphan/bupropion Step requirement — risk of denial if prerequisites missing

    Coverage for Auvelity will be denied unless the patient has tried a generic SSRI or SNRI AND bupropion (each at least a 1‑day supply within the prior 180 days), unless an allowed exception (suicidal ideation or current/prior Auvelity use) is documented.

    • Ensure documentation shows both the SSRI/SNRI and bupropion trials within the 180‑day look‑back to avoid automatic denial.
    • If invoking the suicidal‑ideation exception, include clinical notes supporting that condition.
    Denial Risk

    Prior tablet trial required — denial risk for Raldesy without tablet trial

    Coverage may be denied for Raldesy if the patient has not tried a tablet dosage form of generic trazodone (at least a 1‑day supply within the prior 180 days) and no applicable exception is documented.

    • Confirm dispensing or administration of a generic trazodone tablet within the 180‑day look‑back before requesting approval.
    • If the patient cannot swallow tablets, include clinical documentation to support the swallowing‑inability exception.
    DocumentationProvider should document presence of suicidal ideation or current/prior use to support exception-based approval.
    Prior tablet trial
    Prior tablet trial definitionUse of a generic trazodone tablet dosage form for at least a 1-day supply within the prior 180 days satisfies the Step 1 tablet requirement.
    Formulation requirementThe requirement specifies a tablet dosage form (generic trazodone tablets such as 50 mg).
    Look-back windowPrior 180 days is used to determine whether the tablet trial occurred.
    Swallowing inability exception
    Swallowing inability exceptionIf the patient has difficulty swallowing tablets or cannot swallow tablets, Raldesy may be approved without a prior tablet trial.
    Alternate justificationsApproval may also be granted if the patient is currently taking Raldesy or has taken Raldesy in the past.
    Documentation neededProvider should document the swallowing impairment or prior/current use of Raldesy to support approval without tablet trial.

    Auvelity initial therapy

    Auvelity initial therapy

    SSRI/SNRI + Bupropion: Trial of a generic SSRI or SNRI AND bupropion (≥1-day supply each in prior 180 days).both classes

    Suicidal ideation or current/prior use are exceptions.

    Trazodone initial therapy

    Trazodone initial therapy

    Step 1 vs Step 2: Step 1: trazodone 100 mg or 150 mg tablets. Step 2: Raldesy 10 mg/mL oral solution.

    No additional criteria provided in this part.

    Step 1: Tablet trial

    Initial therapy preferred agents

    Preferred initial agents: Generic trazodone tablets (50 mg, 100 mg, 150 mg) as step 1 before Raldesy